Claims for Adverse Reactions to Vaccines and Drugs under the Medicaid and Medically Needy Programs:
HB 149, titled "Cody's Law: Florida No Vaccine-Injured Patient Left Behind," would require the Agency for Health Care Administration (AHCA) to expedite the review and payment of Medicaid and medically needy claims involving severe, debilitating, life-threatening, or lifelong injuries allegedly caused by vaccines, immunizing agents, or emergency countermeasure drugs. The bill applies only when the vaccine, immunizing agent, or drug is recommended by the U.S. Food and Drug Administration or the Florida Department of Health.
The bill also directs AHCA to publish on its website a list of medical conditions tied to these products, a list of potential adverse reactions from product inserts that are considered critical or disabling, any new related medical conditions, and any future vaccines, immunizing agents, drugs, or treatments deemed appropriate by the agency or diagnosing physicians. It further requires the agency to inform website visitors about the new claims process and to seek federal approval if needed, while adopting rules to implement the section. The act would take effect July 1, 2025.
HB 149 would create new section 409.9043, Florida Statutes, adding a specific Medicaid and medically needy claims process for adverse reactions to vaccines and emergency countermeasure drugs. In practice, it would impose new administrative duties on AHCA to prioritize certain claims, maintain public-facing informational lists, and potentially coordinate with federal authorities to ensure the policy fits within Medicaid requirements. The bill would affect Medicaid enrollees, medically needy recipients, physicians diagnosing vaccine-related injuries, and AHCA’s claims and rulemaking operations.
There is limited recorded committee discussion or voting history in the provided materials, so the overall sentiment is difficult to gauge from debate. The bill’s introduction and naming suggest strong support from sponsors for patients who believe they were harmed by vaccines or related countermeasure drugs, with a focus on faster access to benefits and treatment. However, the fact that the bill died in the Health Care Facilities & Systems Subcommittee indicates it did not advance, suggesting either insufficient support, procedural limits, or unresolved concerns among members.
The main points of contention likely center on whether Medicaid should create a special expedited pathway for vaccine- or drug-related injury claims, how such injuries would be verified, and whether the agency should publish lists that may imply medical causation or expand beyond established clinical standards. There may also be concern about federal Medicaid compliance, the scope of products covered, and the administrative burden on AHCA. Supporters would likely emphasize patient access and recognition of serious injuries, while skeptics may question the evidentiary basis, program costs, and policy implications of singling out these claims.